Chronic myelogenous leukemia.
O'Brien
Susan
S
Berman
Ellin
E
Bhalla
Kapil
K
Copelan
Edward A
EA
Devetten
Marcel P
MP
Emanuel
Peter D
PD
Erba
Harry P
HP
Greenberg
Peter L
PL
Moore
Joseph O
JO
Przepiorka
Donna
D
Radich
Jerald P
JP
Schilder
Russell J
RJ
Shami
Paul
P
Smith
B Douglas
BD
Snyder
David S
DS
Soiffer
Robert J
RJ
Tallman
Martin S
MS
Talpaz
Moshe
M
Wetzler
Meir
M
D000465:Algorithms; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D001549:Benzamides; D002471:Cell Transformation, Neoplastic; D019457:Chromosome Breakage; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D003561:Cytarabine / Q000627:therapeutic use; D020732:Cytogenetic Analysis; D018450:Disease Progression; D004347:Drug Interactions; D050939:Gene Fusion; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D000068877:Imatinib Mesylate; D007372:Interferons / Q000627:therapeutic use; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000209:etiology / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity; D017410:Practice Guidelines as Topic / Q000592:standards*; D011743:Pyrimidines / Q000627:therapeutic use / Q000633:toxicity; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000378:metabolism; D012074:Remission Induction; D055502:Secondary Prevention; D014178:Translocation, Genetic; D014184:Transplantation, Homologous
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D011993:Recombinant Fusion Proteins; D003561:Cytarabine; D000068877:Imatinib Mesylate; D007372:Interferons